Source-grounded facts extracted from Tenaya Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Tenaya Therapeutics, Inc. shareholders approved Approval of the Company’s Amended and Restated 2021 Equity Incentive Plan at the 2026-05-27 meeting.
“The stockholders approved the amendment and restatement of the Company’s 2021 Equity Incentive Plan.”
Tenaya Therapeutics, Inc. shareholders approved Ratification of the Appointment of Independent Registered Public Accounting Firm at the 2026-05-27 meeting.
“The stockholders ratified the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.”
Tenaya Therapeutics, Inc. shareholders approved Election of Class II Directors at the 2026-05-27 meeting.
“Each director nominee was duly elected to serve until the 2029 annual meeting of stockholders and until their successor is duly elected and qualified, subject to earlier resignation or removal.”
Tenaya Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2026.
“On May 6, 2026, Tenaya Therapeutics, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2026”
Tenaya Therapeutics, Inc. reported financial results for the fourth quarter and full year ended December 31, 2025.
“On March 11, 2026, Tenaya Therapeutics, Inc. issued a press release announcing its financial results for the quarter and full year ended December 31, 2025”
Tenaya Therapeutics, Inc. entered into Collaboration Agreement with Alnylam Pharmaceuticals, Inc. valued at up to $10.0 million (effective 2026-03-04).
“On March 4, 2026, Tenaya Therapeutics, Inc. (the “Company”) entered into a collaboration agreement (the “Collaboration Agreement”) with Alnylam Pharmaceuticals, Inc. (“Alnylam”)”
Tenaya Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).
“January 28, 2026, Tenaya Therapeutics, Inc. (the “Company”) received a letter from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of shares of the Company’s common stock for the 30 consecutive business day period between December 12, 2025, through January 27, 2026, the Company did not meet the minimum bid price of $1.00 per share required for continued listing on the Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1). The letter also indicated that the Company will be provided with a”
Tenaya Therapeutics, Inc. entered into Underwriting Agreement with Leerink Partners LLC and Piper Sandler & Co. valued at approximately $60 million (effective 2025-12-11).
“On December 11, 2025, Tenaya Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC and Piper Sandler & Co., as representatives (the “Representatives”) of the underwriters listed therein (the “Underwriters”), relating to the issuance and sale in a firm commitment underwritten public offering (the “Offering”) of 50,000,000 units (the “Units”), at a public offering price of $1.20 per Unit, consisting of one share of the Company’s common stock, par value $0.0001 per share (the “Common Stock”, and such shares, the “Shares”) and one warrant to purchase one share of Common Stock at an exercise price of $1.50 per share that is exercisable for a period of five years from the date of issuance (a “Warrant”). Under the terms of the Underwriting Agreement, the Underwriters have agreed to purchase the Units from the Company at a price of $1.128 per share. All of the Units in the Offering are being sold by the Company. The S”
Tenaya Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).
“April 15, 2025, Tenaya Therapeutics, Inc. (the “Company”) received a letter from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of shares of the Company’s common stock for the 30 consecutive business day period between March 3, 2025, through April 12, 2025, the Company did not meet the minimum bid price of $1.00 per share required for continued listing on the Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1). The letter also indicated that the Company will be provided with a complia”
Tenaya Therapeutics, Inc. announced a restructuring with charges of approximately $1.6 million to $2.7 million.
“as planned. Key capabilities to support early research have also been retained. In connection with the Restructuring Plan, Tenaya estimates that it will incur approximately $1.6 million to $2.7 million of aggregate charges, primarily related to employee cash severance and continuing health benefits. Tenaya expects to recognize substantially all of the charges by”
Tomohiro Higa was appointed as Interim Principal Accounting Officer at Tenaya Therapeutics, Inc..
“Effective February 6, 2025, Mr. Tomohiro Higa, Senior Vice President, Finance, of Tenaya Therapeutics, Inc. (the “Company”), will assume the role of Interim Principal Accounting Officer (“Interim PAO”) for the Company in addition to his role as Senior Vice President, Finance.”
Chihiro Saito was appointed as Interim Principal Accounting Officer at Tenaya Therapeutics, Inc..
“Ms. Chihiro Saito, Tenaya’s Senior Vice President, Accounting and Financial Operations, will assume the role of Interim PAO for the Company”
Faraz Ali was appointed as Interim Principal Financial Officer at Tenaya Therapeutics, Inc..
“Faraz Ali, Chief Executive Officer of Tenaya, will become Interim PFO in addition to his role as Chief Executive Officer.”
Leone Patterson departed as Chief Financial and Business Officer at Tenaya Therapeutics, Inc..
“Effective August 14, 2024, upon Ms. Leone Patterson ceasing to be the Chief Financial and Business Officer, Principal Financial Officer (PFO) and Principal Accounting Officer (PAO) for Tenaya”
Leone Patterson resigned as Chief Financial and Business Officer at Tenaya Therapeutics, Inc..
“On July 19, 2024, Leone Patterson, Chief Financial and Business Officer (“CFBO”) of Tenaya Therapeutics, Inc. (“Tenaya” or the “Company”), advised Tenaya that she was resigning from her role as CFBO, Principal Financial Officer and Principal Accounting Officer to pursue another opportunity.”
Jin-Long Chen resigned as Director at Tenaya Therapeutics, Inc..
“On June 25, 2024, Jin-Long Chen submitted his resignation as a director of Tenaya Therapeutics, Inc.”
Tenaya Therapeutics, Inc. reported financial results for first quarter ended March 31, 2024.
“On May 14, 2024, Tenaya Therapeutics, Inc. (“Tenaya”) issued a press release announcing Tenaya’s financial results for the quarter ended March 31, 2024 (“the Earnings Press Release”). The full text of the Earnings Press Release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.”
Tenaya Therapeutics, Inc. announced a restructuring with charges of $1.3 million to $1.5 million (approximately 22% of the workforce).
“Employees impacted by the Workforce Reduction were notified on May 13, 2024, and represent approximately 22% of the workforce. In connection with the Workforce Reduction, Tenaya estimates that it will incur approximately $1.3 million to $1.5 million, of aggregate charges, primarily related to employee cash severance and continuing health benefits, which costs are expected to be substantially recognized during the second quarter of 2024.”
Tenaya Therapeutics, Inc. reported the fourth quarter and full year ended December 31, 2023 results: net income Net loss was $29.9 million, or $0.40 per share for the fourth quarter ended December 31, 2023. For the full year 2023, n, EPS $0.40 per share for the fourth quarter ended December 31, 2023. For the full year 2023, net loss was $124.1 million, or.
“Net loss was $29.9 million, or $0.40 per share for the fourth quarter ended December 31, 2023. For the full year 2023, net loss was $124.1 million, or $1.68 per share.”
Tenaya Therapeutics, Inc. entered into Underwriting Agreement with Leerink Partners LLC and Cowen and Company, LLC, as representatives of the underwriters valued at approximately $50.0 million (effective 2024-02-07).
“On February 7, 2024, Tenaya Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC and Cowen and Company, LLC, as representatives (the “Representatives”) of the underwriters listed therein (the “Underwriters”), relating to the issuance and sale in an underwritten registered direct offering (the “Offering”) of 8,888,890 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share, at an offering price of $4.50 per share and pre-funded warrants (the “Pre-Funded Warrants”) to purchase 2,222,271 shares of the Company’s common stock at an offering price of $4.499 per underlying share.”
Tenaya Therapeutics, Inc. reported the third quarter ended September 30, 2023 results: net income $29.1 million, or $0.39 per share, EPS $0.39 per share.
“Net loss for the quarter ended September 30, 2023, was $29.1 million, or $0.39 per share.”
Tenaya Therapeutics, Inc. reported the second quarter ended June 30, 2023 results: net income $33.3 million, EPS $0.45 per share.
“Net loss for the quarter ended June 30, 2023, was $33.3 million, or $0.45 per share.”
Tenaya Therapeutics, Inc.: Amendment to certificate of incorporation to adopt officer exculpation provisions under Delaware law (effective 2023-06-08).
“On June 8, 2023, immediately following the vote on proposal 3 at the 2023 Annual Meeting of Stockholders (the “Annual Meeting”) of Tenaya Therapeutics, Inc. (the “Company”), the Company filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation to reflect recently adopted Delaware law provisions regarding officer exculpation, which amendment was effective upon filing.”
Tenaya Therapeutics, Inc. shareholders approved Approval of Amendment to Amended and Restated Certificate of Incorporation to Reflect Recently Adopted Delaware Law Provisions Regarding Officer Exculpation.
“Proposal 3: Approval of Amendment to Amended and Restated Certificate of Incorporation to Reflect Recently Adopted Delaware Law Provisions Regarding Officer Exculpation For Against Abstain Broker Non-Votes 55,753,278 1,173,172 8,120 3,354,787 The stockholders approved the amendment to the Company’s Amended and Restated Certificate of Incorporation to reflect recently adopted Delaware law provisions regarding officer exculpation.”
Tenaya Therapeutics, Inc. shareholders approved Ratification of the Appointment of Independent Registered Public Accounting Firm at the 2023-12-31 meeting.
“Proposal 2: Ratification of the Appointment of Independent Registered Public Accounting Firm For Against Abstain Broker Non-Votes 60,277,871 11,275 211 0 The stockholders ratified the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.”
Tenaya Therapeutics, Inc. shareholders approved Election of Class II Directors.
“Proposal 1: Election of Class II Directors Name of Director Nominee For Withheld Broker Non-Votes Amy Burroughs, M.B.A. 56,813,999 120,571 3,354,787 Jin-Long Chen, Ph.D. 54,315,499 2,619,071 3,354,787 Catherine Stehman-Breen, M.D. 56,678,838 255,732 3,354,787 Each director nominee was duly elected to serve until the 2026 annual meeting of stockholders and until their successor is duly elected and qualified, subject to earlier resignation or removal.”
Tenaya Therapeutics, Inc. reported financial results for first quarter ended March 31, 2023.
“On May 10, 2023, Tenaya Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2023.”
Tenaya Therapeutics, Inc.: Amended and restated bylaws to enhance procedural mechanics for stockholder nominations and other business, update DGCL provisions, and make other updates (effective 2023-03-16).
“On March 16, 2023, the Board of Directors (the “Board”) of Tenaya Therapeutics, Inc. (“Tenaya”) approved Tenaya’s Amended and Restated Bylaws (the “Amended and Restated Bylaws”).”
Tenaya Therapeutics, Inc. reported the fourth quarter and full year ended December 31, 2022 results: net income Net loss was $33.5 million, or $0.61 loss per share for the fourth quarter ended December 31, 2022. For the full year 20.
“Tenaya Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results”
Amy Burroughs was appointed as Class II Director at Tenaya Therapeutics, Inc..
“On December 5, 2022, the Board appointed Amy Burroughs, to serve as a Class II director, with a term expiring at the Company’s 2023 annual meeting of stockholders.”
Eli Casdin resigned as Director at Tenaya Therapeutics, Inc..
“On December 5, 2022, Eli Casdin submitted his resignation as a director of Tenaya Therapeutics, Inc. (the “Company”) and as a member of the Company’s Audit Committee (the “Audit Committee”).”
Tenaya Therapeutics, Inc. entered into Underwriting Agreement with Morgan Stanley & Co. LLC and Piper Sandler & Co., as representatives of the several underwriters named therein valued at approximately $75.0 million (effective 2022-11-16).
“On November 16, 2022, Tenaya Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Morgan Stanley & Co. LLC and Piper Sandler & Co., as representatives (the “Representatives”) of the several underwriters named therein (collectively, the “Underwriters”), relating to the issuance and sale (the “Offering”) of 22,613,307 shares of the Company’s common stock, par value $0.0001 per share, at a price to the public of $2.60 per share (the “Underwritten Shares”) and pre-funded warrants (the “Pre-Funded Warrants”) to purchase 6,236,693 shares of the Company’s common stock at a price to the public of $2.599 per underlying share.”
Tenaya Therapeutics, Inc. reported third quarter ended September 30, 2022 results: net income Net loss for the second quarter ended September 30, 2022, was $30.7 million, or $0.74 per share., EPS $0.74 per share.
“Tenaya Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2022.”
Karah Parschauer was appointed as Director at Tenaya Therapeutics, Inc..
“appointed Karah Parschauer to the Board and as a member of the audit committee of the Board”
June Lee was appointed as Director at Tenaya Therapeutics, Inc..
“On November 19, 2021, the Board appointed June Lee, M.D., to serve as a Class III director”
JeenJoo Kang resigned as Director at Tenaya Therapeutics, Inc..
“On November 17, 2021, JeenJoo Kang, Ph.D., submitted her resignation as a director of Tenaya Therapeutics, Inc.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.